Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 10/20 | 1.00 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13809028 | 1.00 | LTA4H (1.00) | LTA4HFFAR1MEN1KMT2AHRH3 | |
| SCHEMBL990950 | 1.00 | LTA4H (1.00) | LTA4HFFAR1MEN1KMT2AHRH3 | |
| Hydrochloric Acid SCHEMBL4314376 | 0.99 | LTA4H (0.98) | LTA4HFFAR1MEN1KMT2AHRH3 | |
| Hydrochloric Acid SCHEMBL4313840 | 0.99 | LTA4H (0.98) | LTA4HFFAR1MEN1KMT2AHRH3 | |
| Hydrochloric Acid SCHEMBL4313837 | 0.99 | LTA4H (0.98) | LTA4HFFAR1MEN1KMT2AHRH3 | |
| SCHEMBL13809121 | 0.97 | LTA4H (1.00) | LTA4HFFAR1MEN1KMT2AHRH3 | |
| SCHEMBL13809093 | 0.97 | LTA4H (1.00) | LTA4HFFAR1MEN1KMT2AHRH3 | |
| Hydrochloric Acid SCHEMBL4318355 | 0.96 | LTA4H (0.98) | LTA4HFFAR1MEN1KMT2AHRH3 | |
| Hydrochloric Acid SCHEMBL4307168 | 0.96 | LTA4H (0.98) | LTA4HFFAR1MEN1KMT2AHRH3 | |
| Hydrochloric Acid SCHEMBL4307174 | 0.96 | LTA4H (0.98) | LTA4HFFAR1MEN1KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011011598-A1 | PROCESS FOR PREPARING 4- { (S) -2- (4-(4-CHLOROPHENOXY) PHENOXYMETHYL) PYRROLIDIN-1-YL) } BUTYRIC ACID AND SALTS THEREOF | DECODE GENETICS EHF (IS) | 2011-01-27 | — | — | WO | claimed |
| EP-4724069-A2 | METHODS OF TREATING LIPEDEMA AND LYMPHATIC DISEASE OF THE SUBCUTANEOUS TISSUE | Celltaxis, LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2024254377-A2 | METHODS OF TREATING LIPEDEMA AND LYMPHATIC DISEASE OF THE SUBCUTANEOUS TISSUE | CELLTAXIS, LLC (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20240398793-A1 | Methods of Treating Lymphedema | CELLTAXIS LLC (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4444419-A2 | METHODS OF TREATING LYMPHEDEMA | Celltaxis, LLC (US) | 2024-10-16 | — | — | EP | disclosed |
| US-12006329-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240050392-A1 | COMPOSITIONS AND METHODS FOR IMPROVED TREATMENT OF PLATINUM-BASED CHEMOTHERAPEUTIC RESISTANT TUMORS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2024-02-15 | — | — | US | disclosed |
| WO-2023107608-A2 | METHODS OF TREATING LYMPHEDEMA | CELLTAXIS, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20090163462-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS, EHF (IS) | 2009-06-25 | — | — | US | disclosed |
| US-7402684-B2 | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENECTICS EHF. (IS) | 2008-07-22 | — | — | US | disclosed |
| US-7402684-B2 | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENECTICS EHF. (IS) | 2008-07-22 | — | — | US | disclosed |
| WO-2007040681-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007040682-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078263-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078263-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006329-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | LTA4H 3561/4885FFAR1 4335/4885MEN1 2643/4885 |
| US-20090163462-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | LTA4H 1/4885FFAR1 668/4885MEN1 4613/4885 |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | LTA4H 1/4885FFAR1 668/4885MEN1 4613/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | LTA4H 3561/4885FFAR1 4335/4885MEN1 2643/4885 |
| US-20070078263-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | LTA4H 1/4885FFAR1 668/4885MEN1 4613/4885 |
| US-20240398793-A1 | Methods of Treating Lymphedema | LTB4R, LTA4H, LTB4R2 | LTA4H 2/4885FFAR1 852/4885MEN1 3193/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | LTA4H 3561/4885FFAR1 4335/4885MEN1 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.